James Hall, MD
Interventional Cardiology · Kearney, NENPI 1336437359
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $25,153 of the $36,495 with a category attached, or 68.9%. Medtronic accounts for 62.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $20,787 and has fallen 74.7% since, to $5,264 in 2025.
Across 430 payments — averaging $84.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- Abbott$4K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- Shockwave Medical, Inc$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$468
- plus $3K from 25 others
What the payments were for
- Travel & lodging$25,15369%
- Food & beverage$11,32731%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 191 | $22,952 |
| Abbott | 49 | $3,532 |
| Boston Scientific | 12 | $3,052 |
| Edwards Lifesciences | 17 | $2,342 |
| Shockwave Medical, Inc | 6 | $1,323 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $468 |
| Novartis | 19 | $376 |
| Amgen | 22 | $329 |
| Johnson & Johnson | 21 | $296 |
| AstraZeneca | 7 | $264 |
| Atricure, Inc. | 5 | $256 |
| Abiomed | 4 | $228 |
| Penumbra, Inc. | 7 | $193 |
| Pfizer | 6 | $108 |
| Irhythm Technologies, Inc. | 5 | $98 |
| Boehringer Ingelheim | 6 | $97 |
| Merck | 5 | $91 |
| Amarin Pharma, Inc. | 3 | $65 |
| Heartflow, Inc. | 2 | $64 |
| Aurinia Pharma U.S., Inc. | 3 | $63 |
| Stryker | 2 | $58 |
| Philips North America LLC | 3 | $46 |
| Chiesi USA, Inc. | 2 | $33 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Bayer | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| Novo Nordisk | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Cvrx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$2,763
- CARDIOMEMS$2,564
- CoreValve Evolut$1,971
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,855
- Reveal LINQ$1,628
- COREVALVE EVOLUT R$1,457
- SYMPLICITY G3$1,419
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,211
- Advisa$474
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$209
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$158
How this compares
$36,495 in reported general payments places this provider in the 85th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 32 | $26,353 |
| XareltoRivaroxaban | 33 | $23,981 |
| Repatha SureclickEvolocumab | 11 | $8,578 |
| Nebivolol Hcl | 20 | $1,499 |
| Ranolazine ErRanolazine | 13 | $1,309 |
| Bumetanide | 27 | $845 |
| Metoprolol Succinate | 65 | $586 |
| Potassium Chloride | 45 | $582 |
| Torsemide | 35 | $434 |
| ClopidogrelClopidogrel Bisulfate | 32 | $386 |
| Atorvastatin Calcium | 41 | $365 |
| Amiodarone Hcl | 19 | $311 |
| Furosemide | 55 | $283 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $243 |
| Bisoprolol Fumarate | 11 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $376 | $26,35332 claims |
| Johnson & JohnsonXarelto | $296 | $23,98133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Kearney
- Daniel McGowanKearney$9K
- John WatersKearney$4K
- Vinayak NagarajaKearney$4K
- Sean DenneyKearney$1K
- Panayotis Alain EfstratiouKearney$722
- Brock CookmanLincoln$782K
- Himanshu AgarwalOmaha$541K
- Matthew JohnsonLincoln$162K
- Poonam VelagapudiOmaha$142K
- Steven MartinLincoln$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.